Chloroquine’s primary and best-established use is the prevention and treatment of malaria caused by Plasmodium species sensitive to the drug. It accumulates in the parasite’s food vacuole, disrupting heme detoxification and leading to parasite death. Beyond malaria, chloroquine has recognized indications in rheumatology for treating chronic inflammatory disorders: it is used off-label or as an alternative to hydroxychloroquine for rheumatoid arthritis, systemic lupus erythematosus (SLE), and certain dermatologic autoimmune conditions because of its immunomodulatory properties. Clinicians may also consider chloroquine for other conditions in controlled, evidence-based contexts, but current practice favors hydroxychloroquine where available due to a more favorable safety profile.
Dosage of chloroquine depends on the indication, patient weight, renal and hepatic function, and local resistance patterns for malaria. For acute uncomplicated malaria in adults caused by chloroquine-sensitive strains, common dosing is an initial loading dose followed by maintenance doses over two days; for example, 600 mg base (equivalent to 1,000 mg chloroquine phosphate) initially, then 300 mg base at 6, 24, and 48 hours—totaling 1,500 mg base. For malaria prophylaxis, lower weekly doses (e.g., 300 mg base weekly) are typical, starting 1–2 weeks before travel and continuing for 4 weeks after return. In rheumatologic indications, chronic dosing is lower and continuous—often 250–500 mg daily of chloroquine phosphate depending on body weight and organ function. Long-term therapy requires periodic assessment of cumulative dose; ophthalmologic monitoring is essential to detect retinal toxicity early. Always calculate dosing based on actual body weight and follow local or institutional guidelines; pediatric dosing is weight-based and must be prescribed by a clinician experienced in pediatric infectious disease or rheumatology.
Chloroquine has a narrow therapeutic index and can cause serious adverse effects, so careful patient selection and monitoring are critical. Retinopathy is a well-known, potentially irreversible risk with long-term use; baseline and regular ophthalmologic exams (including visual fields and retinal imaging) are recommended, particularly after five years of therapy or sooner with higher cumulative doses. Cardiotoxicity, including conduction abnormalities and cardiomyopathy, can occur—watch for unexplained syncope, palpitations, or ECG changes. Patients with pre-existing heart disease, electrolyte abnormalities, or on other QT-prolonging drugs need special caution.
Dose adjustments are necessary in renal or hepatic impairment since elimination may be altered. Avoid abrupt discontinuation in certain conditions without medical guidance. During pregnancy and breastfeeding, the benefits and risks must be weighed; chloroquine crosses the placenta and is present in breast milk but may still be indicated in malaria where maternal treatment is urgent. Always inform the prescriber of a full medical history, current medications, pregnancy status, and any visual or cardiac symptoms before starting chloroquine.
Absolute contraindications include known hypersensitivity to chloroquine, other 4-aminoquinolines, or any component of the formulation. Use is contraindicated in patients with pre-existing retinopathy attributable to chloroquine or hydroxychloroquine. Caution or avoidance is advised in those with porphyria, known glucose-6-phosphate dehydrogenase (G6PD) deficiency when risks outweigh benefits, and in patients with significant baseline cardiac conduction abnormalities without cardiology evaluation. Children and infants require weight-based assessment and specialist oversight before initiation.
Common side effects include gastrointestinal upset (nausea, vomiting, diarrhea, abdominal pain), headache, dizziness, and itching. Many adverse effects are dose-related and may improve with dose adjustment or dosing with food. Less common but clinically important effects include dermatologic reactions (rashes, hyperpigmentation), neuromuscular symptoms (myopathy, muscle weakness), and neuropsychiatric events such as mood changes, irritability, or rarely psychosis.
Serious adverse events to monitor for are retinal toxicity with progressive visual field defects, corneal deposits causing transient vision changes, and cardiac toxicity manifesting as arrhythmias or cardiomyopathy. Hematologic abnormalities such as anemia or leukopenia may occur rarely. Report any new visual symptoms, palpitations, severe muscle weakness, or unexplained bleeding to a healthcare provider immediately. Regular monitoring and early intervention reduce the risk of permanent harm.
Chloroquine interacts with a range of medications. Notable interactions include other QT-prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics, fluoroquinolones, antipsychotics) which can increase the risk of torsades de pointes and sudden cardiac events. Concomitant use with digoxin or cyclosporine may increase serum concentrations of those drugs; therapeutic drug monitoring and dose adjustments may be necessary. Co-administration with antiepileptics like phenobarbital or carbamazepine can reduce chloroquine plasma levels by inducing hepatic enzymes, potentially reducing efficacy.
Chloroquine can alter glucose metabolism and may potentiate hypoglycemic effects of antidiabetic agents, so blood glucose monitoring is advised. Coadministration with medications that lower seizure threshold should be approached cautiously. Always provide a complete medication list to the prescriber and pharmacist—including over-the-counter drugs and supplements—to assess for potential interactions and plan monitoring strategies.
Another available option is to review Hydrochlorothiazide information online while considering different healthcare needs.If you miss a dose of chloroquine, take it as soon as you remember unless it is almost time for the next dose. Do not double the next dose to catch up; doubling increases the risk of toxicity. For weekly malaria prophylaxis schedules, if a weekly dose is missed, take it as soon as possible and resume the regular schedule—contact a clinician if multiple weekly doses are missed. For acute treatment courses, follow-up with your prescriber for guidance if doses are missed, as effectiveness may be compromised.
Chloroquine overdose is a medical emergency. Symptoms of acute overdose can include severe cardiovascular collapse, hypotension, arrhythmias, hypokalemia, seizures, coma, and respiratory failure. Rapid onset of symptoms may occur within hours. If overdose is suspected, seek immediate emergency care or contact a poison control center. Management is supportive and may include activated charcoal if ingestion is recent, airway support, aggressive cardiovascular monitoring, correction of electrolyte disturbances, and admission to an intensive care unit. There is no specific antidote; early detection and supportive care are crucial to improving outcomes.
Store chloroquine tablets at room temperature away from moisture and heat, typically between 20–25°C (68–77°F) unless otherwise indicated on the label. Keep in the original container and out of reach of children and pets. Do not use tablets that are discolored, broken, or past the expiration date. Dispose of unused medication according to local waste disposal regulations or take-back programs; do not flush medications down the toilet unless instructed. Follow specific storage instructions provided by the dispensing pharmacy or manufacturer.
In the United States, chloroquine is a regulated medication typically dispensed with a prescription from a licensed healthcare provider. Regulatory status can vary with indication and local policy; pharmacies and clinicians must comply with federal and state prescribing laws. Some online or international pharmacies may offer alternative access models; patients should verify legality and safety before purchasing. Sunshine Pharmacy provides a legal, structured solution for patients seeking chloroquine without a formal in-person prescription by offering telemedicine evaluations and licensed prescriber review where permitted by law. This model ensures prescriptions are issued following clinical assessment, appropriate screening, and adherence to regulatory standards, while offering convenient delivery and pharmacist support.
Before starting chloroquine, discuss your full medical history with a qualified clinician—especially eye disease, heart problems, liver or kidney impairment, pregnancy, and current medications. Baseline and periodic ophthalmologic exams are required for long-term therapy to detect early signs of retinopathy. Report any visual disturbances, cardiac symptoms, or severe side effects immediately. Avoid alcohol and substances that can exacerbate side effects. Pregnant or breastfeeding patients should consult their obstetrician and infectious disease or rheumatology specialist; in malaria, timely treatment is essential and clinicians will weigh maternal and fetal risks. Keep emergency contact information and medication lists accessible, and ensure follow-up appointments for monitoring are scheduled.
Patients prescribed chloroquine should receive clear instructions on how to take the medication, what to expect, and when to seek medical help. Take tablets with food or a full glass of water to reduce gastrointestinal upset. Adherence to dosing schedules and monitoring appointments (eye exams, ECG if indicated, blood tests) is essential to minimize risk. Avoid self-medicating or sharing medication; never increase dose without clinician approval. Keep a record of any side effects and communicate changes to your healthcare team. If purchasing through services like Sunshine Pharmacy’s telemedicine-enabled option, ensure you complete the clinical screening, understand the counseling provided by pharmacists, and retain access to ongoing support for questions or adverse event reporting.
Chloroquine is an antimalarial medication from the 4-aminoquinoline class that also has immunomodulatory effects; it has been used to treat and prevent malaria and to manage autoimmune conditions such as rheumatoid arthritis and lupus under medical supervision.
Chloroquine accumulates in parasite-containing acidic vacuoles and interferes with heme detoxification in malaria parasites; it also alters lysosomal pH and immune signaling in human cells, which helps its anti-inflammatory effects in autoimmune disease.
Primary uses include treatment and, historically, prophylaxis of certain forms of malaria, and off-label or adjunctive use for autoimmune disorders like systemic lupus erythematosus and rheumatoid arthritis, always guided by a clinician.
Current high-quality evidence does not support routine use of chloroquine for COVID-19; studies failed to show consistent benefit and raised safety concerns, so its use for COVID-19 is not recommended outside clinical trials and expert guidance.
Chloroquine is given orally in prescription form; exact dosing and duration depend on indication, weight, and local guidelines. Never self-prescribe—use only under a healthcare provider’s direction.
Common side effects include nausea, abdominal pain, headache, dizziness, pruritus (especially in some populations), and transient visual disturbances.
Serious concerns include retinal toxicity (progressive retinopathy), cardiotoxicity including QT prolongation and arrhythmias, severe hypoglycemia, neuromyopathy, and rare hematologic reactions; these require prompt medical evaluation.
Yes—cumulative, long-term use can cause irreversible retinopathy and vision loss. Baseline and periodic ophthalmologic monitoring are recommended for prolonged therapy.
People with known hypersensitivity to 4-aminoquinolines, preexisting retinopathy, significant cardiac conduction disease or QT prolongation, electrolyte abnormalities, and certain drug interactions should avoid or use chloroquine only with specialist oversight; pregnancy and breastfeeding require personalized medical advice.
Yes—important interactions include other QT-prolonging drugs (increasing arrhythmia risk), certain antacids that reduce absorption, drugs affecting glucose (risk of hypoglycemia), and drugs altering metabolizing enzymes; always review current medications with your prescriber.
Overdose can be life-threatening with severe cardiovascular collapse, seizures, and coma; immediate emergency medical care is essential—seek urgent help rather than waiting or attempting home remedies.
Chloroquine can be used in children when indicated, but dosing must be weight-based and supervised by a healthcare provider; toxicity risk from overdose is especially serious in pediatric patients.
Chloroquine was widely used for malaria prophylaxis but effectiveness depends on regional resistance patterns; many areas now require alternative prophylaxis. Consult travel health guidance for up-to-date regional recommendations.
For malaria, chloroquine acts on blood-stage parasites and can reduce symptoms within 24–48 hours in susceptible infections; for autoimmune conditions, symptomatic benefit may take weeks to months. Time to effect varies by condition.
Baseline and periodic ophthalmologic examinations, cardiac evaluation if risk factors or symptoms appear, and routine clinical follow-up for signs of toxicity are standard; frequency depends on dose, duration, and individual risk.
Ask your primary care provider, infectious disease or rheumatology specialist, pharmacist, or travel medicine clinic; rely on current guidelines from reputable health authorities for condition-specific recommendations.
Hydroxychloroquine is a related 4-aminoquinoline that is generally considered to have a somewhat more favorable safety profile and lower retinopathy risk at equivalent doses; however, both drugs can cause similar serious adverse effects and require monitoring.
Hydroxychloroquine is usually preferred for autoimmune conditions (like lupus and rheumatoid arthritis) because of better tolerability and comparable efficacy; clinicians commonly favor hydroxychloroquine when available.
Both have been used in pregnancy when clinically indicated; hydroxychloroquine is more frequently preferred in pregnant patients for autoimmune disease due to its safety record, but pregnancy decisions should be individualized by obstetric and specialty care teams.
Mefloquine is often active against chloroquine-resistant Plasmodium falciparum and is used where chloroquine resistance is common; mefloquine has its own notable neuropsychiatric side effects, so choice depends on resistance patterns and patient tolerance.
Amodiaquine is another 4-aminoquinoline used in combination therapies for malaria; it may retain activity where chloroquine fails but carries risks of rare but serious hepatotoxicity and agranulocytosis, so safety profiles differ and require monitoring.
They target different parasite stages: chloroquine clears blood-stage (schizont) parasites, while primaquine targets liver hypnozoites of P. vivax and P. ovale to prevent relapse. Primaquine can cause hemolysis in G6PD deficiency, a key distinction.
Quinine (and intravenous artesunate) has historically been used for severe malaria and has a different side effect profile (cinchonism, hypoglycemia); chloroquine is oral and not suitable for severe cases or where resistance is present.
Quinacrine is an older antimalarial with historical use and distinct adverse effects (e.g., discoloration, gastrointestinal upset, possible psychiatric effects); it is rarely used today compared with chloroquine or hydroxychloroquine except in niche situations.
Yes—chloroquine resistance in P. falciparum is widespread in many regions, limiting its usefulness; alternative agents or combination therapies (like artemisinin-based combinations) are preferred in areas with documented resistance.
Artemisinin-based combination therapies (ACTs) are the global first-line treatment for uncomplicated P. falciparum in most regions due to high efficacy against resistant strains; chloroquine is only appropriate where parasites remain susceptible.
Cross-resistance can occur between chloroquine and some other 4-aminoquinolines in resistant parasite strains, affecting treatment choices; local resistance surveillance guides which agents remain effective.
Clinicians may choose chloroquine when infecting parasites are known to be chloroquine-sensitive, when the drug is the guideline-recommended first-line agent in that region, or for specific non-malarial autoimmune indications after weighing risks and benefits.
